Biotechnology
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restric...
2025-11-19 08:00
2314
CRScube acquires Mednet to expand global eClinical capabilities
SEOUL, South Korea and MINNEAPOLIS, Nov. 18, 2025 /PRNewswire/ -- CRScube has announced the successful acquisition of Mednet, marking a key milestone in its global strategic growth and expansion into the North American market. The transaction unites two respected eClinical technology vendors with...
2025-11-18 17:00
953
INSTITUTE OF NEURODIVERSITY, NEUROPOWER WORLD, AND SINGAPORE BRINGS NEURODESIGN TO THE FOREFRONT OF SINGAPORE'S URBAN PLANNING
Hazleen Ahmad, Founder of Neuropower World and Chair & Founder of ION Singapore, to launch pilot projects and training programmes embedding neurodesign into workplaces, housing, parks, and transport hubs SINGAPORE, Nov. 18, 2025 /PRNewswire/ -- The Institute of Neurodiversity (ION) Singapore and ...
2025-11-18 09:00
842
Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract de...
2025-11-17 22:26
1088
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection...
2025-11-17 22:06
1800
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
HONG KONG, Nov. 17, 2025 /PRNewswire/ -- The APAC Precision Oncology Conference
2025
2025-11-17 13:45
1022
Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
* Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for patients acrossJapan * Similar marketing authorization...
2025-11-14 17:43
890
Amorepacific Named CES Innovation Award Honoree for Advanced Electronic Skin Platform
- Co-developed by Amorepacific and MIT, Skinsight™ receives recognition as the company's seventh consecutive win at CES - Applied in substantiating the efficacy of a Sulwhasoo product, with functionality in skin-aging analytics backed by published research SEOUL, South Korea, Nov. 14, 2025 /PR...
2025-11-14 09:00
1087
Fosun International Receives "ESG & Corporate Sustainability Excellence Award" from Hong Kong Economic Journal
HONG KONG, Nov. 14, 2025 /PRNewswire/ -- On 13 November 2025, Hong Kong Economic Journal (HKEJ), Hong Kong's first Chinese-language financial newspaper, hosted the "ESG & Sustainability Awards of Excellence 2025" ceremony. At the event, Fosun International received the "ESG & Corporate Sustainab...
2025-11-14 09:00
2598
KHB Showcases the Enhanced FOCUS PEGASUS MF200 -- Redefining Efficiency in Veterinary Diagnostics
XI'AN, China, Nov. 13, 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd., a subsidiary of KHB Group and an innovator in veterinary point-of-care testing (POCT) solutions, presents the enhanced FOCUS PEGASUS MF200 Automatic Multifunctional Veterinary Analyzer — a next-generation system ...
2025-11-13 15:18
918
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 16:12
930
/C O R R E C T I O N -- Heng Ren Partners/
In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issuedNov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at th...
2025-11-12 12:31
2561
Alpha IVF Singapore uses Advanced Fertility Genomic Screening and Artificial Intelligence Embryo Scoring to help couples become parents
SINGAPORE, Nov. 12, 2025 /PRNewswire/ -- In-vitro fertilisation (IVF) has become increasingly prominent due to societal shifts towards delayed childbearing, infertility issues, and advances in medical technology that have improved success rates. At Alpha IVF Singapore, Advanced Fertility Genomic ...
2025-11-12 10:00
832
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89 Zr-girentuximab) in metastatic triple negative breast cancer (mTNB...
2025-11-12 04:00
1342
Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +14% CER[1] (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. andEurope was the driver of this strong performance. * United States: DKK 9,955 million (+22% CER; +19...
2025-11-12 03:11
1136
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
BOSTON and SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at theAssociation for Molecular Pa...
2025-11-11 21:01
915
Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
HONG KONG, Nov. 11, 2025 /PRNewswire/ -- On 8 November, Guo Guangchang, Chairman of Fosun International, attended the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025. During the conference, Guo Guangchang stated, "At this crucial juncture today,China's pharmaceutical innovation ...
2025-11-11 15:41
2136
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
* Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) * Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-...
2025-11-10 21:30
2239
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical data reveal potential applications in hemolyti...
2025-11-10 21:15
1141
Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycer...
2025-11-10 12:00
2009
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 291 media titles]
2026-01-05 12:14
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 283 media titles]
2026-01-06 10:45
Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
[Picked up by 281 media titles]
2026-01-07 10:00
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 280 media titles]
2026-01-01 10:00
Space Summit 2026 to Convene Global Leaders in Singapore to Address the Growing Space Economy
[Picked up by 272 media titles]
2026-01-07 15:27Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
8931
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
2026-01-01 10:00
8139
Domestic GPU Leader Biren Technology Listed on Hong Kong Stock Exchange
2026-01-02 17:41
7546
